# ADMA Biologics Fundamentals

ADMA | Stock | ## USD 3.34 0.02 0.60% |

ADMA Biologics fundamentals help investors to digest information that contributes to ADMA Biologics' financial success or failures. It also enables traders to predict the movement of ADMA Biologics Stock. The fundamental analysis module provides a way to measure ADMA Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ADMA Biologics stock.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. ADMA Biologics | Select Account or Indicator |

**M**, whereas Consolidated Income is forecasted to decline to (73.5

**M**).

## ADMA Biologics Current Asset Analysis

ADMA Biologics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets. 2019 | 2020 | 2021 | 2022 (projected) | |

Revenues USD | 29.35 M | 42.22 M | 80.94 M | 87.33 M |

Revenues | 29.35 M | 42.22 M | 80.94 M | 87.33 M |

Current Asset | = | Cash | + | Deposits | + | Liquid Assets |

## Current ADMA Biologics Current Asset | 21.29 M |

Most of ADMA Biologics' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ADMA Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

## ADMA Biologics Current Asset Historical Pattern

Today, most investors in ADMA Biologics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ADMA Biologics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of ADMA Biologics current asset as a starting point in their analysis.

ADMA Biologics Current Asset |

Share

Timeline |

Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.

Compare to competition |

## ADMA Biologics Total Assets

## Total Assets | ## 298.06 Million |

In accordance with the recently published financial statements, ADMA Biologics has a Current Asset of 21.29

**M**. This is 99.01% lower than that of the Biotechnology sector and 97.99% lower than that of the Health Care industry. The current asset for all United States stocks is 99.77% higher than that of the company.## ADMA Biologics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining ADMA Biologics's current stock value. Our valuation model uses many indicators to compare ADMA Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ADMA Biologics competition to find correlations between indicators driving ADMA Biologics's intrinsic value. More Info.ADMA Biologics is number one stock in profit margin category among related companies. It is number one stock in cash flow from operations category among related companies . ADMA Biologics Profit Margin is projected to slightly grow based on the last few years of reporting. The past year's Profit Margin was at -79.66. Comparative valuation analysis is a catch-all model that can be used if you cannot value ADMA Biologics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ADMA Biologics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ADMA Biologics' earnings, one of the primary drivers of an investment's value.## ADMA Biologics Operating Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ADMA Biologics' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ADMA Biologics could also be used in its relative valuation, which is a method of valuing ADMA Biologics by comparing valuation metrics of similar companies.ADMA Biologics is currently under evaluation in operating margin category among related companies.

## ADMA Biologics Current Valuation Drivers

We derive many important indicators used in calculating different scores of ADMA Biologics from analyzing ADMA Biologics' financial statements. These drivers represent accounts that assess ADMA Biologics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ADMA Biologics' important valuation drivers and their relationship over time.

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

Net Income Per Employee | (148.34 K) | (206.74 K) | (153.76 K) | (185.61 K) | (135.95 K) | (146.69 K) | |

Revenue Per Employee | 77.15 K | 53.41 K | 93.47 K | 103.45 K | 153.59 K | 122.49 K | |

Average Assets | 70.77 M | 101.03 M | 121.57 M | 199.93 M | 245.84 M | 265.25 M | |

Earnings Before Interest Taxes and Depreciation Amortization EBITDA | (37.8 M) | (56.97 M) | (36.84 M) | (60.14 M) | (53.11 M) | (57.3 M) | |

Earnings Before Interest Taxes and Depreciation Amortization USD | (37.78 M) | (56.77 M) | (36.03 M) | (59.82 M) | (53.1 M) | (54.49 M) | |

Earnings before Tax | (43.76 M) | (65.74 M) | (48.28 M) | (75.75 M) | (71.65 M) | (73.53 M) | |

Average Equity | 17.56 M | 32.94 M | 29.81 M | 83.21 M | 117.01 M | 126.25 M | |

Enterprise Value | 144.06 M | 108.35 M | 272.24 M | 222.01 M | 336.55 M | 268.81 M | |

Free Cash Flow | (39.95 M) | (64.77 M) | (80.01 M) | (114.73 M) | (125.88 M) | (129.19 M) | |

Invested Capital | 84.56 M | 89.07 M | 163.05 M | 219.17 M | 284.98 M | 307.48 M | |

Invested Capital Average | 58.43 M | 86.97 M | 137.66 M | 200.67 M | 261.9 M | 282.58 M | |

Market Capitalization | 126.5 M | 110.78 M | 237.27 M | 184.37 M | 276.1 M | 226.57 M | |

Tangible Asset Value | 99.64 M | 81.34 M | 120.4 M | 201.7 M | 270.99 M | 292.39 M | |

Working Capital | 52.9 M | 34.9 M | 71.79 M | 133.79 M | 178.35 M | 192.43 M |

## ADMA Biologics Fundamentals

Return On Equity | (0.69) % | |||

Return On Asset | (0.11) % | |||

Profit Margin | (0.54) % | |||

Operating Margin | (0.36) % | |||

Current Valuation | 755.38 M | |||

Shares Outstanding | 196.78 M | |||

Shares Owned by Insiders | 2.01 % | |||

Shares Owned by Institutions | 79.95 % | |||

Number of Shares Shorted | 21.74 M | |||

Price to Earning | (1.55) X | |||

Price to Book | 6.35 X | |||

Price to Sales | 5.07 X | |||

Revenue | 80.94 M | |||

Gross Profit | 1.17 M | |||

EBITDA | (79.21 M) | |||

Net Income | (71.65 M) | |||

Cash and Equivalents | 52.42 M | |||

Cash per Share | 0.27 X | |||

Total Debt | 94.87 M | |||

Debt to Equity | 1.32 % | |||

Current Ratio | 7.94 X | |||

Book Value Per Share | 0.51 X | |||

Cash Flow from Operations | (112.37 M) | |||

Short Ratio | 6.76 X | |||

Earnings Per Share | (0.49) X | |||

Target Price | 5.0 | |||

Number of Employees | 527 | |||

Beta | 1.0 | |||

Market Capitalization | 661.17 M | |||

Total Asset | 276.25 M | |||

Retained Earnings | (271.68 M) | |||

Working Capital | 17.07 M | |||

Current Asset | 21.29 M | |||

Current Liabilities | 4.22 M | |||

Z Score | -12.3 | |||

Net Asset | 276.25 M |

## About ADMA Biologics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze ADMA Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADMA Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADMA Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.Last Reported | Projected for 2022 | ||

Deferred Revenue | 2.1 M | 2.5 M | |

Cost of Revenue | 79.8 M | 86.1 M | |

Revenues | 80.9 M | 87.3 M | |

Revenue to Assets | 0.29 | 0.25 | |

Revenue Per Employee | 153.6 K | 122.5 K |

## Be your own money manager

Our tools can tell you how much better you can do entering a position in ADMA Biologics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.## Did you try this?

### Run Idea Analyzer Now

## Idea AnalyzerAnalyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |

All Next | Launch Module |

## Pair Trading with ADMA Biologics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ADMA Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ADMA Biologics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to ADMA Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ADMA Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ADMA Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ADMA Biologics to buy it.

The correlation of ADMA Biologics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ADMA Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ADMA Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for ADMA Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Please continue to ADMA Biologics Piotroski F Score and ADMA Biologics Altman Z Score analysis. You can also try Transaction History module to view history of all your transactions and understand their impact on performance.

## Complementary Tools for analysis

When running ADMA Biologics price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.

Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | Go | |

Companies DirectoryEvaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | Go | |

Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets | Go | |

Equity ValuationCheck real value of public entities based on technical and fundamental data | Go | |

Global CorrelationsFind global opportunities by holding instruments from different markets | Go | |

Commodity Channel IndexUse Commodity Channel Index to analyze current equity momentum | Go | |

Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios | Go | |

Pattern RecognitionUse different Pattern Recognition models to time the market across multiple global exchanges | Go |

Is ADMA Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA Biologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Market Capitalization 661.2 M | Quarterly Revenue Growth YOY 0.99 | Return On Assets (0.11) | Return On Equity (0.69) |

The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA Biologics that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine ADMA Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.